Avita (4735) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 豪展

Avita (4735) reported revenue of NT$105.1 million for Oct 2026, +61.5% year on year and +4.3% from the previous month. Revenue for Jan–Oct 2026 was NT$910.7 million (+20.9% year on year).

Year-on-year revenue growth: 4 months in a row. →

In Oct 2026, it ranked No. 71 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$60 million24/10Nov 2024 NT$81.1 millionDec 2024 NT$67.4 millionJan 2025 NT$69.8 millionFeb 2025 NT$41.7 million25/02Mar 2025 NT$87.1 millionApr 2025 NT$75 millionMay 2025 NT$81.7 millionJun 2025 NT$96.5 million25/06Jul 2025 NT$80.2 millionAug 2025 NT$82.5 millionSep 2025 NT$73.6 millionOct 2025 NT$65.1 million25/10Nov 2025 NT$78.8 millionDec 2025 NT$104.7 millionJan 2026 NT$60.6 millionFeb 2026 NT$51.2 million26/02Mar 2026 NT$102.3 millionApr 2026 NT$107.7 millionMay 2026 NT$84.1 millionJun 2026 NT$82.1 million26/06Jul 2026 NT$114.8 millionAug 2026 NT$102 millionSep 2026 NT$100.8 millionOct 2026 NT$105.1 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$105.1 million+61.5%+4.3%
Sep 2026NT$100.8 million+37.0%-1.1%
Aug 2026NT$102 million+23.6%-11.2%
Jul 2026NT$114.8 million+43.1%+39.7%
Jun 2026NT$82.1 million-14.9%-2.4%
May 2026NT$84.1 million+3.0%-21.9%
Apr 2026NT$107.7 million+43.7%+5.3%
Mar 2026NT$102.3 million+17.4%+99.9%
Feb 2026NT$51.2 million+22.7%-15.6%
Jan 2026NT$60.6 million-13.1%-42.1%
Dec 2025NT$104.7 million+55.3%+32.7%
Nov 2025NT$78.8 million-2.8%+21.1%
Oct 2025NT$65.1 million+8.5%-11.5%
Sep 2025NT$73.6 million-32.7%-10.9%
Aug 2025NT$82.5 million+4.2%+2.9%
Jul 2025NT$80.2 million-0.7%-16.9%
Jun 2025NT$96.5 million+1.8%+18.1%
May 2025NT$81.7 million+23.1%+9.0%
Apr 2025NT$75 million-19.6%-13.9%
Mar 2025NT$87.1 million-8.7%+109.0%
Feb 2025NT$41.7 million+22.9%-40.3%
Jan 2025NT$69.8 million+6.0%+3.5%
Dec 2024NT$67.4 million+46.8%-16.9%
Nov 2024NT$81.1 million+58.5%+35.1%
Oct 2024NT$60 million+4.3%-45.1%

Jan–Oct 2026 cumulative: NT$910.7 million (+20.9% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Avita vs PEC / Avita vs Lotus Pharm / Avita vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

舊客戶新產品出貨增加。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16